The TGA has warned advertising or promoting unapproved peptides was likely to breach Australian therapeutic goods advertising laws
Advanced therapies to maximize results
10.1371/journal.pone.0129146 [DOI] [PMC free article] [PubMed] [Google Scholar] 32.Nie LJ, Liang J, Shan F, Xu YY, Yan CY, Zhou X, et al
(5.4, 7.1) Hypersensitivity Reactions: There have been postmarketing reports of serious allergic and hypersensitivity reactions in patients treated with JANUVIA such as anaphylaxis, angioedema, and exfoliative skin conditions including Stevens-Johnson syndrome
GLP-1 and GIP receptor agonists in the treatment of Parkinsons disease: translational systematic review and meta-analysis protocol of clinical and preclinical studies
Footnotes References 1